Home › Funds › Blue Owl Capital Holdings LP › CGEM
Blue Owl Capital Holdings LP position in CGEM
CULLINAN THERAPEUTICS INC · Health Care
Blue Owl Capital Holdings LP reported holding 1,399,899 shares of CGEM (CULLINAN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$21.5M, representing 4.04% of its reported portfolio and ranking #8 among its reported holdings. Blue Owl Capital Holdings LP has disclosed CGEM holdings in 12 of the last 12 reported quarters, going back to Q4 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Blue Owl Capital Holdings LP's CGEM position evolved
Blue Owl Capital Holdings LP first disclosed a stake in CGEM in Q4 2023 at 3,419,842 shares (US$34.8M). The position peaked in Q1 2024 at 2,924,842 shares, worth US$49.8M. Across 12 filings, Blue Owl Capital Holdings LP increased the stake 3 time(s), trimmed it 8 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,399,899 shares valued at US$21.5M — a reduction of -139,865 shares quarter over quarter.. Notable position changes include a 30% trim in Q2 2024 (shares fell 4% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 3.42M | $34.85M | New |
| Q1 2024 | 2.92M | $49.84M | Reduce |
| Q2 2024 | 2.05M | $35.74M | Reduce |
| Q3 2024 | 2.01M | $33.66M | Reduce |
| Q4 2024 | 2.37M | $28.88M | Add |
| Q1 2025 | 2.44M | $18.44M | Add |
| Q2 2025 | 2.39M | $17.97M | Reduce |
| Q3 2025 | 2.51M | $14.89M | Add |
| Q4 2025 | 2.35M | $24.33M | Reduce |
| Q1 2026 | 1.91M | $27.14M | Reduce |
| Q2 2026 | 1.54M | $28.04M | Reduce |
| Q3 2026 | 1.40M | $21.49M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CGEM and 13F data
CGEM (CULLINAN THERAPEUTICS INC) is a Health Care company. 33 other funds we track also report a position in CGEM — the largest reported positions include MPM BioImpact LLC (US$177.2M), Lynx1 Capital Management LP (US$163.2M), BVF INC/IL (US$104.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CGEM
- MPM BioImpact LLC 9.73M sh · $177.21M · Q2 2026
- Lynx1 Capital Management LP 8.96M sh · $163.23M · Q2 2026
- BVF INC/IL 5.75M sh · $104.72M · Q2 2026
- Kynam Capital Management, LP 3.11M sh · $56.71M · Q2 2026
- RTW INVESTMENTS, LP 2.36M sh · $43.05M · Q2 2026
- Siren, L.L.C. 1.79M sh · $27.53M · Q3 2026
- Venrock Adviser, LLC 1.38M sh · $25.13M · Q2 2026
- BOOTHBAY FUND MANAGEMENT, LLC 1.08M sh · $19.71M · Q2 2026
- Affinity Asset Advisors, LLC 875.76K sh · $15.95M · Q2 2026
- BOONE CAPITAL MANAGEMENT LLC 704.44K sh · $12.83M · Q2 2026
- Elmind Capital, LP 690.00K sh · $12.56M · Q2 2026
- TWIN FOCUS CAPITAL PARTNERS, LLC 595.49K sh · $10.84M · Q2 2026
More on Blue Owl Capital Holdings LP
FAQ
How long has Blue Owl Capital Holdings LP held CGEM?
Blue Owl Capital Holdings LP has disclosed CGEM holdings in 12 of the last 12 reported quarters, going back to Q4 2023.
What is Blue Owl Capital Holdings LP's current position in CGEM?
As of Q3 2026, Blue Owl Capital Holdings LP holds 1.40M shares of CGEM (CULLINAN THERAPEUTICS INC), valued at $21.49M, representing 4.04% of its reported portfolio and ranking #8.
Has Blue Owl Capital Holdings LP been buying or selling CGEM?
In the latest 13F filing (Q3 2026), Blue Owl Capital Holdings LP reduced its position in CGEM. The position peaked in Q1 2024 at 2.92M shares.
Which other funds hold CGEM?
Other major institutional holders of CGEM include MPM BioImpact LLC, Lynx1 Capital Management LP, BVF INC/IL, among 33 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.